Biogen says Alzheimer's drug slowed disease, but shares tumble on skepticism
July 25, 2018 at 17:34 PM EDT
Patients taking the highest dosage of BAN2401 — which is one of multiple Alzheimer's drugs that Biogen is developing — experienced a 30 percent reduction in cognitive decline, the company said. But its shares took a nosedive amid skepticism about the strength of the data.
